Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01292486 · ClinicalTrials.gov registry record · NA
Evaluation of the Spectra Optia® Mononuclear Cell Collection Procedure
A NA study, sponsored by Terumo BCT.
- Completed
- Registry status
- NA
- Development phase
- 32
- Enrollment target
NCT01292486 is a NA study that has completed, run by Terumo BCT. The registered enrollment target is 32 participants.
The verdict
NCT01292486, a NA study, has completed, sponsored by Terumo BCT.
- COMPLETED
- Registry status
- NA
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of this investigation is to establish that hematopoetic stem cells collected on a new centrifugal blood separator, CaridianBCT's Spectra Optia Apheresis System, are able to reconstitute the hematopoetic systems of patients treated with myeloablative therapy, equivalent to hematopoetic cells harvested on the predicate COBE® Spectra platform.
Interventions
- DEVICE Spectra Optia Apheresis System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2011-02 |
| Est. Completion | 2011-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01292486
The ClinicalTrials.gov registry entry for NCT01292486 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Terumo BCT, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Spectra Optia Apheresis System is the first listed.
NCT01292486 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01292486 about?
NCT01292486 is a clinical study titled "Evaluation of the Spectra Optia® Mononuclear Cell Collection Procedure". The purpose of this investigation is to establish that hematopoetic stem cells collected on a new centrifugal blood separator, CaridianBCT's Spectra Optia Apheresis System, are able to reconstitute the hematopoetic systems of patients treated with myeloablative therapy, equivalent to hematopoetic ce...
What is the current status of trial NCT01292486?
This trial is currently completed. It is a NA study. The enrollment target is 32 participants. The study started on 2011-02. Estimated completion is 2011-12.
What interventions are being tested in trial NCT01292486?
The interventions under investigation include: Spectra Optia Apheresis System (DEVICE).
Who is sponsoring clinical trial NCT01292486?
This trial is sponsored by Terumo BCT, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.